Phase 2 3 COMPANION 002 study findings released by Compass Therapeutics

Phase 2 3 COMPANION 002 study findings released by Compass Therapeutics
Compass presents biliary cancer trial data

Compass Therapeutics has announced the presentation of results from its Phase 2 3 COMPANION 002 trial targeting previously treated advanced biliary tract cancer.

The findings are being shared at the ESMO 2026 conference and have been published in the Journal of Clinical Oncology. This update provides new data on the companys investigational efforts in oncology, focusing on a patient population with limited treatment options.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.